Small-molecule compound SYG-180-2-2 attenuates Staphylococcus aureus virulence by inhibiting hemolysin and staphyloxanthin production

Lulin Rao, Yanlei Xu, Li Shen, Xinyi Wang, Huilin Zhao, Bingjie Wang, Jiao Zhang, Yanghua Xiao, Yinjuan Guo, Yaoguang Sheng, Lixia Cheng, Zengqiang Song, Fangyou YuFrontiers in Cellular and Infection Microbiology 2022 · DOI

TL;DR

This paper introduces SYG-180-2-2, a novel small molecule compound that effectively reduces the virulence of Staphylococcus aureus without killing the bacteria directly. By inhibiting key virulence factors like hemolysin and staphyloxanthin production, SYG-180-2-2 makes S. aureus more susceptible to host defenses and reduces infection severity in animal models, offering a promising new avenue for combating antibiotic-resistant infections.

What Problem Does This Paper Address?

Staphylococcus aureus is a major cause of hospital and community-acquired infections, and its increasing resistance to antibiotics, particularly Methicillin-resistant S. aureus (MRSA), poses a significant global health threat. Traditional antibacterial approaches focus on killing bacteria, which can drive the evolution of resistance. An alternative strategy is "virulence factor therapy," which aims to disarm the bacteria by inhibiting their ability to cause disease, making them easier for the host's immune system to clear. This paper addresses the need for new anti-virulence agents by investigating the efficacy of a previously synthesized compound, SYG-180-2-2, against S. aureus virulence.

Methods

The researchers employed a multi-pronged approach to assess SYG-180-2-2's anti-virulence properties:

  • Minimum Inhibitory Concentration (MIC) and Growth Assays: Standard broth microdilution methods were used to determine if SYG-180-2-2 inhibited bacterial growth or had any direct antibacterial effect.
  • Hemolysis Assay: This assay measured the ability of S. aureus supernatants to lyse red blood cells, indicating hemolysin activity. They used both qualitative (visual observation of red blood cell lysis) and quantitative (spectrophotometric measurement of hemoglobin release) methods.
  • Quantitative Enzyme-Linked Immunosorbent Assay (ELISA): Used to specifically quantify the amount of alpha-hemolysin in the bacterial supernatant.
  • Pigment Production Assay: Assessed the production of staphyloxanthin, a golden pigment produced by S. aureus, by measuring absorbance at 450 nm after methanol extraction.
  • Oxidative Stress Sensitivity Assays:
    • Hydrogen Peroxide (H₂O₂) Killing Assay: Bacteria were exposed to H₂O₂ after treatment with SYG-180-2-2 to determine if their survival rate was affected.
  • Human Whole-Blood Killing Assay: Bacteria were incubated with human blood to assess their susceptibility to host immune clearance.
  • RNA Isolation and RT-qPCR: Quantitative Polymerase Chain Reaction (qPCR) was used to measure the expression levels of key virulence genes (e.g., hla, hlb, crtM, crtN, sigB, sodA, sodM, katA) and regulatory genes (saeR, saeS) in treated versus untreated bacteria.
  • Larval Infection Model (Galleria mellonella): This invertebrate model was used to assess the compound's toxicity and its effect on bacterial virulence in vivo.
  • Mouse Skin Abscess Model: A mammalian model was used to evaluate SYG-180-2-2's ability to reduce skin abscess formation, bacterial burden, and inflammation caused by S. aureus infection.
  • Histopathological Analysis: Skin tissue from the mouse model was examined microscopically to assess the extent of inflammation and tissue damage.

Datasets

Not discussed in the paper. The study utilized bacterial strains SA75 (clinical isolate) and Newman (ATCC 25904) for their experiments.

Key Insights and Ideas

  • Targeting Virulence, Not Viability: The most striking finding is that SYG-180-2-2 significantly attenuates S. aureus virulence without exhibiting direct antibacterial activity or affecting bacterial growth. This "disarming" approach is crucial for developing therapies that circumvent antibiotic resistance.
  • Dual Inhibition of Key Virulence Factors: SYG-180-2-2 effectively targets two critical virulence factors: hemolysin (specifically downregulating hlb gene expression) and staphyloxanthin production. This dual action likely contributes to its overall efficacy.
  • Staphyloxanthin's Role in Immune Evasion: The inhibition of staphyloxanthin, a pigment known for its antioxidant properties, significantly increases S. aureus's susceptibility to oxidative stress (like H₂O₂) and human whole blood. This highlights how virulence factors can directly contribute to immune evasion.
  • SaeRS Regulatory Pathway Involvement: The compound's ability to downregulate the saeR and saeS genes, which are key regulators of virulence factors like hemolysin, provides a mechanistic link between SYG-180-2-2 and reduced hemolysin activity.
  • In Vivo Efficacy Demonstrated: The compound showed significant promise in both a Galleria mellonella larval model and a mouse skin abscess model, reducing bacterial burden, abscess size, and inflammation, underscoring its potential as a therapeutic agent.

Key Results

  • SYG-180-2-2 had no apparent antibacterial activity (MIC > 128 µg/mL) and did not affect bacterial growth curves at the tested concentration (4 µg/mL).
  • It strongly inhibited hemolytic activity, reducing it by 80.70-85.97% in SA75 and 50.00-56.14% in Newman. However, alpha-hemolysin levels (measured by ELISA) were not significantly affected, suggesting the inhibition is primarily via beta-hemolysin (hlb).
  • Staphyloxanthin production was almost completely inhibited (96.04-96.26% inhibition) at 4 µg/mL, rendering the bacteria colorless.
  • SYG-180-2-2 treatment significantly increased the susceptibility of S. aureus to hydrogen peroxide (survival reduced by ~9-fold for SA75 and ~850-fold for Newman) and human whole blood.
  • RT-qPCR revealed significant downregulation of virulence-related genes: hlb (hemolysin), crtM, crtN, and sigB (staphyloxanthin synthesis), as well as oxidative stress-related genes sodA, sodM, and katA. The regulatory genes saeR and saeS were also downregulated.
  • In the Galleria mellonella model, SYG-180-2-2 was not toxic to larvae, and bacterial virulence was significantly reduced, with death rates decreasing by 30% (SA75) and 60% (Newman).
  • In the mouse skin abscess model, SYG-180-2-2 treatment significantly reduced abscess size, bacterial load, and inflammatory infiltration.

Limitations and Future Work

  • Limited Safety Data: While topical application in mice and injection in larvae showed no toxicity, the safety of SYG-180-2-2 via intravenous or oral administration has not been evaluated, and further trials are needed.
  • Mechanism of Action Elucidation: While the study identified key genes and pathways affected by SYG-180-2-2, the precise molecular mechanism of action, particularly regarding the lack of effect on alpha-hemolysin expression despite saeR downregulation, requires further investigation.
  • Broader Spectrum and Resistance: The study focused on specific S. aureus strains. Future work should explore the compound's efficacy against a wider range of S. aureus strains, including different MRSA lineages, and assess its potential to overcome or prevent resistance development.
  • Combination Therapies: The authors suggest that SYG-180-2-2's multi-target anti-virulence approach could be beneficial, and future research could explore its combination with other antibacterial or anti-virulence agents.

Summary updated

Abstract

Multi-drug resistant <i>Staphylococcus aureus</i> infection is still a serious threat to global health. Therefore, there is an urgent need to develop new antibacterial agents based on virulence factor therapy to overcome drug resistance. Previously, we synthesized SYG-180-2-2 (C<sub>21</sub>H<sub>16</sub>N<sub>2</sub>OSe), an effective small molecule compound against biofilm. The aim of this study was to investigate the anti-virulence efficacy of SYG-180-2-2 against <i>Staphylococcus aureus</i>. MIC results demonstrated no apparent antibacterial activity of the SYG-180-2-2. The growth curve assay showed that SYG-180-2-2 had nonlethal effect on <i>S. aureus</i>. Besides, SYG-180-2-2 strongly inhibited the hemolytic activity and staphyloxanthin synthesis in <i>S. aureus</i>. Inhibition of staphyloxanthin by SYG-180-2-2 enhanced the sensitivity of <i>S. aureus</i> to oxidants and human whole blood. In addition, SYG-180-2-2 significantly decreased the expression of <i>saeR</i>-mediated hemolytic gene <i>hlb</i> and staphyloxanthin-related <i>crtM</i>, <i>crtN</i> and <i>sigB</i> genes by quantitative polymerase chain reaction (qPCR). Meanwhile, the expression of oxidative stress-related genes <i>sodA</i>, <i>sodM</i> and <i>katA</i> also decreased. <i>Galleria Mellonella</i> assay revealed that SYG-180-2-2 was not toxic to larvae. Further, the larvae infection model showed that the virulence of bacteria was significantly reduced after 4 μg/mL SYG-180-2-2 treatment. SYG-180-2-2 also reduced skin abscess formation in mice by reducing bacterial burden and subcutaneous inflammation. In conclusion, SYG-180-2-2 might be a promising agent to attenuate the virulence of <i>S. aureus</i> by targeting genes associated with hemolytic activity and staphyloxanthin synthesis.
BibTeX
@inproceedings{rao2022small,
  author = {Lulin Rao and Yanlei Xu and Li Shen and Xinyi Wang and Huilin Zhao and Bingjie Wang and Jiao Zhang and Yanghua Xiao and Yinjuan Guo and Yaoguang Sheng and Lixia Cheng and Zengqiang Song and Fangyou Yu},
  title = {{Small-molecule compound SYG-180-2-2 attenuates Staphylococcus aureus virulence by inhibiting hemolysin and staphyloxanthin production}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2022},
  doi = {10.3389/fcimb.2022.1008289},
}
Figure